The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

HIV experts are concerned that Yeztugo’s full potential might remain unrealized. Priced at $14,109 per injection, or $2,352 per month, Yeztugo's cost could be another hurdle.

HIV- 1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection taking only Yeztugo, because Yeztugo alone is not a complete regimen for HIV-1 treatment.

This photo provided by Gilead Sciences shows packaging for the company's HIV prevention medication, Yeztugo, (lenacapvir) at a manufacturing facility in La Verne, Calif., in June 2025. Credit: AP ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs.